NeXT Personal MRD test predicts NSCLC outcomes, phase III trial shows

City of Hope to evaluate Quest Diagnostics’ Haystack MRD for guiding patient management in multiple cancers

Quest Diagnostics, a provider of diagnostic information services, announced that City of Hope is implementing Haystack MRD, a circulating-tumor DNA minimal residual disease test, for clinical trial participants with solid tumor cancers to help guide disease management for patients being treated for breast, colorectal, ovarian, and prostate cancer.

April 24, 2026

Vol.52 No.16

In Brief

University of Maryland Greenebaum Comprehensive Cancer Center receives $5.5M donation to advance cancer research and patient care

The Marlene and Stewart Greenebaum Family Foundation has donated $5.5 million to the University of Maryland Greenebaum Comprehensive Cancer Center to help advance scientific research and cancer care in Maryland and across the region.

April 17, 2026

Vol.52 No.15

Guest Editorial

America needs a new blueprint for the National Cancer Program
First step: Develop Version 2.0 of Paul Calabresi’s “Cancer at a Crossroads”

Recently, a friend lent me a copy of a decades-old report, and by old, I mean a classic.

April 10, 2026

Vol.52 No.14

By Robert A. Winn

California state-funded institute scraps selection process that put cancer projects at a disadvantage
Cancer researchers are resubmitting applications to the California Institute for Regenerative Medicine

The California Institute for Regenerative Medicine, a state agency tasked with awarding billions of dollars of scientific funding for stem cell and gene therapy, has rescinded a controversial policy that was disrupting the flow of funding to cancer research.

Cancer AI Alliance announces first wave of pilot projects

Cancer AI Alliance announced its first wave of eight pilot projects across a federated learning platform. These projects represent the first wave of the organization’s efforts and aim to demonstrate that it is possible to analyze vast amounts of data while keeping patient privacy secure at the local level.

April 10, 2026

Vol.52 No.14

Guest Editorial

FDA’s guidance on MRD in MM goes beyond the ODAC vote—and that’s where it matters most
Draft guidance consolidates trial design updates for developers

In January, FDA released a draft guidance entitled “Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints to Support Accelerated Approval.” This release came roughly 20 months after the Oncologic Drugs Advisory Committee (ODAC) voted unanimously that minimal residual disease (MRD) negativity, in combination with complete response (CR), is an acceptable primary endpoint to support accelerated approval for multiple myeloma (MM) therapies.

April 03, 2026

Vol.52 No.13

By Nicholas Richardson

NeXT Personal MRD test predicts NSCLC outcomes, phase III trial shows

YOU MAY BE INTERESTED IN

City of Hope to evaluate Quest Diagnostics’ Haystack MRD for guiding patient management in multiple cancers

University of Maryland Greenebaum Comprehensive Cancer Center receives $5.5M donation to advance cancer research and patient care

America needs a new blueprint for the National Cancer Program
First step: Develop Version 2.0 of Paul Calabresi’s “Cancer at a Crossroads”

California state-funded institute scraps selection process that put cancer projects at a disadvantage
Cancer researchers are resubmitting applications to the California Institute for Regenerative Medicine

Cancer AI Alliance announces first wave of pilot projects

FDA’s guidance on MRD in MM goes beyond the ODAC vote—and that’s where it matters most
Draft guidance consolidates trial design updates for developers

Renew today!

Subscriber content

Never miss an issue!

Login

NeXT Personal MRD test predicts NSCLC outcomes, phase III trial shows

YOU MAY BE INTERESTED IN

City of Hope to evaluate Quest Diagnostics’ Haystack MRD for guiding patient management in multiple cancers

University of Maryland Greenebaum Comprehensive Cancer Center receives $5.5M donation to advance cancer research and patient care

America needs a new blueprint for the National Cancer ProgramFirst step: Develop Version 2.0 of Paul Calabresi’s “Cancer at a Crossroads”

California state-funded institute scraps selection process that put cancer projects at a disadvantageCancer researchers are resubmitting applications to the California Institute for Regenerative Medicine

Cancer AI Alliance announces first wave of pilot projects

FDA’s guidance on MRD in MM goes beyond the ODAC vote—and that’s where it matters mostDraft guidance consolidates trial design updates for developers

Never miss an issue!

Login

America needs a new blueprint for the National Cancer Program
First step: Develop Version 2.0 of Paul Calabresi’s “Cancer at a Crossroads”

California state-funded institute scraps selection process that put cancer projects at a disadvantage
Cancer researchers are resubmitting applications to the California Institute for Regenerative Medicine

FDA’s guidance on MRD in MM goes beyond the ODAC vote—and that’s where it matters most
Draft guidance consolidates trial design updates for developers